FARMERS & MERCHANTS TRUST Co OF LONG BEACH Increases Stock Holdings in Danaher Co. (NYSE:DHR)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in Danaher Co. (NYSE:DHR) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,921 shares of the conglomerate’s stock after buying an additional 869 shares during the quarter. Danaher makes up approximately 1.0% of FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s portfolio, making the stock its 24th biggest holding. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Danaher were worth $3,728,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. Patrick M Sweeney & Associates Inc. raised its position in shares of Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas raised its position in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after purchasing an additional 40 shares during the last quarter. Abacus Planning Group Inc. raised its position in shares of Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after purchasing an additional 40 shares during the last quarter. ST Germain D J Co. Inc. raised its position in shares of Danaher by 1.4% in the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after purchasing an additional 41 shares during the last quarter. Finally, Premier Path Wealth Partners LLC raised its position in shares of Danaher by 1.8% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after purchasing an additional 42 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 2.6 %

Danaher stock opened at $273.09 on Tuesday. The business has a 50-day simple moving average of $261.87 and a two-hundred day simple moving average of $255.96. The company has a market cap of $197.23 billion, a P/E ratio of 46.29, a P/E/G ratio of 4.38 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.05 EPS. Analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus lifted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.